Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

BACKGROUND: Therapy for advanced epithelial ovarian cancer (OC) includes first line platinum/taxane-containing chemotherapy and re-treatment with platinum-containing regimens for disease recurrence in patients likely to respond again. Single-agent, non-platinum, cytotoxic agents are commonly used to...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzog, Thomas J., Monk, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590167/
https://www.ncbi.nlm.nih.gov/pubmed/28904804
http://dx.doi.org/10.1186/s40661-017-0050-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590167/
https://www.ncbi.nlm.nih.gov/pubmed/28904804
http://dx.doi.org/10.1186/s40661-017-0050-0

Ejemplares similares